Objective: To identify the mutated gene in a group of patients with an unclassified heritable white matter disorder sharing the same, distinct MRI pattern.
METHODS Patients. We identified 6 patients from 5 unrelated families from our MRI database of more than 3,000 cases with an unclassified leukoencephalopathy using MRI pattern recognition analysis. 5 Patients 3 and 4 are affected siblings. Inclusion criteria were 1) extensive cerebellar cortex signal abnormalities; 2) signal abnormalities in the corpus callosum; and 3) absence of signal abnormalities in the basal ganglia, thalami, and cerebral cortex. Patient 2 was previously published by Wolf et al. 13 In none of the patients a molecular diagnosis was achieved.
S.H.K. and M.S.v.d.K. evaluated the MRIs according to a previous protocol. 5 We retrospectively reviewed the clinical information and laboratory investigations. Upon identification of the mutated gene, we included the MRI of a previously published case (patient 7) in our analysis to confirm consistency of our findings. 14, 15 Standard protocol approvals, registrations, and patient consents. We received approval of the ethical standards committee for our research on patients with unclassified leukoencephalopathies. We received written informed consent for exome sequencing from all guardians of the patients participating in the study.
Whole-exome sequencing. We performed whole-exome sequencing in DNA of patients 2 and 4, using SeqCap EZ Human Exome Library v3.0 kit (Nimblegen) on Hiseq2000 (Illumina, San Diego, CA; detailed information in e-Methods on the Neurology ® Web site at www.neurology.org).
NUBPL mutation analysis. We amplified the 11 exons and intron-exon junctions of the human NUBPL gene (NG_028349.1) by PCR using suitable primers (available upon request) and analyzed these by Sanger sequencing.
Biochemical analysis. Skin fibroblasts of patients 2, 3, 4, and 6 were available and cultured in M199 medium supplemented with 10% fetal calf serum and antibiotics. We measured the enzyme activity of complexes I, II, III, IV, and V, and citrate synthase spectrophotometrically in mitochondria-enriched fractions isolated from fibroblasts and muscle as described. [16] [17] [18] We performed biochemical analysis of NUBPL and complex I assembly with the fibroblasts of patients 3 and 4. We performed 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and 1-and 2dimensional 5% to 15% blue native (BN)-PAGE as previously described. 19 Lanes were loaded with 40 mg (SDS analysis) or 80 mg (BN analysis) of solubilized mitochondrial protein. After electrophoresis, the gels were further processed for in-gel activity assays and Western blotting, as described. 19 We incubated the Western blots using antibodies against NUBPL (kind gift of Prof. R. Lill, Marburg, Germany), complex I subunits NDUFA9 and NDUFS3, and complex II subunit SDHA/70 kDa (MitoSciences, Eugene, OR).
RESULTS MRI findings. Detailed MRI findings are provided in table e-1 and illustrated in figure 1. Initial MRIs (figure 1, A-D, patient 7; I-L, patient 4) of patients 2, 4, 5, 6, and 7, obtained early in the disease course, showed confluent or multifocal cerebral white matter lesions, predominantly affecting the deep frontal and parietal white matter and sparing the U-fibers, internal and external capsules, and central part of the corona radiata under the pericentral cortex. Early MRIs showed prominent signal abnormalities and swelling of the corpus callosum. Callosal fibers connecting the pericentral cortex were relatively preserved ( figure 1D ). Extensive signal abnormalities were present in the cerebellar cortex and subcortical white matter, whereas the cerebellar deep white matter and hilus of the dentate nucleus were spared (figure 1, A, D, I, and L). The inferior part of the cerebellum was less severely affected (figure 1, D and L). The corpus callosum and abnormal cerebral hemispheric white matter were rarefied ( figure 1S ). Contrast enhancement was seen in small areas of the abnormal cerebral white matter and corpus callosum ( figure 1T ). Restricted diffusion was present at the edges of the affected cerebral white matter and corpus callosum (figure 1, Q and R).
Late MRIs (figure 1, E-H, patient 2; M-P, patient 4) were available in patients 1, 2, 3, and 4. In patients 2 and 4, substantial improvement of the cerebral white matter and corpus callosum abnormalities were seen with decrease in both white matter swelling and extent of the white matter abnormalities, whereas the cerebellar abnormalities had worsened (figure 1, E-H, M, N, and P). In patients 1 and 3, only a late MRI was available. In patient 3, subtle signal changes were exclusively seen in the corpus callosum; patient 1 had severe atrophy of the corpus callosum and limited cerebral white matter abnormalities. The cerebellar white matter and cortex were now extensively affected and atrophic in all patients. Prominent lesions were present in the basis pontis and pyramids of the medulla (figure 1, E, H, M, and P). Contrast enhancement was seen in the pons and cerebellar cortex ( Figure 1O ). No diffusion restriction was observed.
Clinical profiles and laboratory results. Detailed clinical characteristics and laboratory results are provided in tables e-2 and e-3. In contrast to the other patients, patient 7 was the only patient in which the early motor development was delayed. Patients presented with insufficient gain or loss of motor skills and signs of cerebellar dysfunction at the end of the first or in the second year of life. On follow-up, signs of continuing development were observed in most patients. Patient 1 experienced continuous slow regression; patients 4, 6, and 7 had episodes of regression of speech and mobility with partial recovery. Five patients developed spasticity. At the most recent clinical follow-up, patients 2 and 3 were able to walk without support. All patients had motor problems due to ataxia. Patient 1 died at 9 years of age of respiratory complications. Cognitive capabilities varied between normal and significantly deficient. No involvement of internal organs was noted.
Plasma and CSF lactate was elevated in most patients. Respiratory chain enzyme assays in muscle and fibroblasts revealed a complex I deficiency in all tested patients, ranging between 27% and 83% of the lowest reference value. The other respiratory chain complexes and complex V showed a normal activity in all patients (tables e-3 and e-4). The diagnosis of complex I deficiency was accomplished between 6 months and 2.5 years after the first MRI. Genetic analysis. We performed whole-exome sequencing in DNA of patients 2 and 4. After filtering of the raw data under the hypothesis of a mitochondrial disorder, NUBPL (MIM*613621), encoding a Fe/S protein involved in complex I assembly, was the only remaining candidate gene with mutations (table e-5). Both patients harbored a heterozygous c.166G.A transition, predicting p.Gly56Arg. Patient 4 also harbored a c.313G.T change, predicting p.Asp105Tyr. Manual analysis of the intron data additionally revealed a heterozygous c.815227T.C change in both patients. Sanger sequencing confirmed these mutations and revealed a frameshift mutation in patient 2: c.667_668insCCTTGTGCTG/p.Glu223Alafs*4. Subsequently, we identified NUBPL mutations in all 4 other patients (see table 1 for all identified NUBPL mutations). The c.166G.A missense mutation and the intronic c.815227T.C branch-site mutation were present on the same allele in all patients. These 2 mutations were previously reported in patient 7 of this report by Calvo et al. 14 within a large exome sequencing project of complex I-deficient patients. We analyzed all identified exonic missense mutations with Polyphen-2, which showed prediction scores of $0.99. The amino acids involved are moderately to highly conserved. The mutations were therefore presumed to be pathogenic. The intronic c.815227T.C mutation was previously shown to cause aberrant splicing of NUBPL mRNA. 15 This mutation is found in the heterozygous state in 1 of 60 controls in the 1000 Genomes database. None of the other identified mutations are present in the public single nucleotide polymorphism databases, including the dbSNP (http://www.ncbi.nlm.nih.gov/projects/ SNP) and 1000 Genomes database.
Biochemical analysis. We performed biochemical analysis of NUBPL and complex I assembly with the fibroblasts of patients 3 and 4. The NUBPL signals obtained in Table 1 Overview of NUBPL both patients were severely decreased as compared with the control (figure 2A ). Both complex I in-gel activity and the amount of fully assembled complex I were decreased in both patients as compared with the control ( figure 2B) , which is compatible with the 50% to 60% reduction of complex I activity measured spectrophotometrically (table e- 4) . We performed 2-dimensional BN/ SDS-PAGE analysis to investigate the effect of mutated NUBPL on the assembly of the peripheral arm of complex I, which contains the Fe-S clusters. We observed that the amount of fully assembled complex I was decreased in both patients ( figure 2C) , consistent with the findings from the BN analysis ( figure 2B) . Moreover, no subassemblies of the peripheral arm of complex I were present in the patients' fibroblasts, in contrast to the control cells ( figure 2C ).
DISCUSSION In this study, we show that the combination of disease definition by MRI pattern analysis and whole-exome sequencing can provide a rapid molecular diagnosis in a small group of patients with the same rare, unclassified leukoencephalopathy of suspected mitochondrial origin. All of our patients harbor mutations in NUBPL, involved in mitochondrial respiratory chain complex I assembly. 20, 21 The MRI pattern observed in the present patients is unique and has not been described in any other disorder of mitochondrial or other origin. 22 The early stages are characterized by a combination of abnormalities involving the cerebellar cortex and deep cerebral white matter and corpus callosum. On follow-up, the corpus callosum and cerebral white matter abnormalities improve and disappear in some patients. In contrast, the cerebellar abnormalities are progressive and brainstem abnormalities appear. One patient with NUBPL mutations has been published before with little clinical information and no MRIs (patient 7). 14 We were able to retrieve his MRI and confirmed that the abnormalities fit perfectly within the pattern observed in the other patients. While preparing this manuscript, an additional patient with NUBPL mutations was published. 23 His MRI at 23 years showed severe cerebellar abnormalities and signal changes of the basis pontis and pyramids of the medulla, characteristic for the late disease stage. 23 We used whole-exome sequencing as a first genetic approach to identify the associated gene. Although highly sensitive in detecting genetic variants, filtering and interpretation of gene variants remain challenging. To selectively reduce the number of variants, specific clues can be used for choosing the correct filters. In our patients, MRI features suggested a mitochondrial disease: multifocal and confluent white matter lesions, rarefied at the center, surrounded by a rim of abnormal but solid tissue, restricted diffusion in these solid rims, additional gray matter abnormalities, patchy contrast enhancement, and elevated lactate in affected brain areas. 22 Our suspicion was substantiated by biochemical evidence of complex I deficiency in all tested patients. In suspected mitochondrial disorders, public mitochondrial databases, such as mitocarta, 24 can substantially reduce the number of candidate genes. However, filtering should be done with caution because not all variants may be detected, such as the insertion of patient 2. Our filter included all genes that contained just one or more variants in both patients. If the filter had been more stringent, NUBPL would have been missed. Besides the c.166G.A missense mutation, the intronic c.815227T.C branch-site mutation was present on the same allele in all patients. Functional in vitro studies have shown that the c.815227T.C variant possesses more pathogenic qualities than the c.166G.A missense mutation. Overexpression of NUBPL protein carrying the missense mutation is able to fully complement complex I activity in an NUBPL-deficient cell line, while the intronic branch-site variant results in aberrant splicing of NUBPL mRNA, 15 which was also confirmed by us (data not shown). The intronic branch-site variant has been found in approximately 1 of 60 controls (1000 Genomes database). Considering the rarity of the disease, it remains inconclusive whether the c.815227T.C variant is pathogenic in its own right, or acts in synergy with the c.166G.A variant.
All tested patients have a complex I deficiency in muscle and fibroblasts, ranging between 83% and 27% of the lowest reference value. There appears to be no correlation between the residual complex I activity levels and the severity of the clinical phenotype, as has been documented before for other complex I defects. 3 Protein analysis of fibroblasts of patients 3 and 4 shows that the mutations in NUBPL result in severely decreased NUBPL protein levels. Furthermore, consistent with the proposed role in complex I assembly, the decreased NUBPL protein levels result in a decreased complex I activity. NUBPL is a chaperone involved in the iron-sulfur cluster assembly in complex I. 20 Complex I contains 7 iron-sulfur clusters, associated with 5 different subunits (NDUFS1, -S7, -S8, -V1, and -V2), which are located in the peripheral arm of the complex. 25 NDUFS7 and -S8 assemble relatively early in the assembly pathway, and defects in these subunits usually do not result in accumulation of assembly intermediates, in contrast to defects in NDUFV1, -V2, and -S1. We observed no accumulation of assembly intermediates of the peripheral arm in our patients and conclude that NUBPL is at least involved in early assembly of the iron-sulfur clusters within the subunits NDUFS7 or -S8 in the peripheral arm of complex I. The 2 previously reported patients with NUBPL mutations were published as single cases with little clinical information and in the first case without MRIs. 14, 23 The consequence of such publications is that the disease phenotype remains uncertain and diagnosis in new patients is difficult. In this study, we demonstrate that NUBPL mutations are associated with a consistent and recognizable MRI pattern that is pathognomonic for the disease. If present in a new patient, no further studies are warranted; sequence analysis of NUBPL is the single necessary test.
